Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 13/20 | 1.00 |
| ▸ | RARB | P10826 | 13/20 | 1.00 |
| ▸ | RARA | P10276 | 9/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 0.76 |
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| O-Demethylated Adapalene SCHEMBL29357074 | 1.00 | RARG (1.00) | RARGRARBRARAMEN1KMT2A | |
| O-Demethylated Adapalene SCHEMBL29357288 | 1.00 | RARG (1.00) | RARGRARBRARAMEN1KMT2A | |
| O-Demethylated Adapalene SCHEMBL29727107 | 1.00 | RARG (1.00) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL6535843 | 0.89 | RARG (0.80) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL29462761 | 0.89 | RARB (0.80) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL20565441 | 0.89 | RARB (0.80) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL26052718 | 0.89 | RARB (0.80) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL6535423 | 0.87 | RARG (0.77) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL8766318 | 0.87 | RARG (0.77) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL13294261 | 0.86 | RARB (0.76) | RARGRARBRARAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4066826-B1 | RETINOIC ACID RECEPTOR GAMMA AGONISTS FOR MUSCLE REPAIR AND REGENERATION | UNIV JEFFERSON (US) | 2024-03-06 | — | — | EP | claimed |
| EP-4066826-A1 | RETINOIC ACID RECEPTOR GAMMA AGONISTS FOR MUSCLE REPAIR AND REGENERATION | Thomas Jefferson University (US) | 2022-10-05 | — | — | EP | claimed |
| US-11339371-B2 | Method for inducing pluripotent stem cells to differentiate into ventricular myocytes in vitro | INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2022-05-24 | — | — | US | claimed |
| US-20220016148-A1 | RETINOIC ACID RECEPTOR GAMMA AGONISTS TO ATTENUATE ANTHRACYCLINE-INDUCED CARDIOTOXICITY | NORTHWESTERN UNIVERSITY | 2022-01-20 | — | — | US | claimed |
| US-11135236-B2 | Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity | NORTHWESTERN UNIVERSITY (US) | 2021-10-05 | — | — | US | claimed |
| EP-2613776-B1 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | UNIV JEFFERSON (US) | 2020-07-29 | — | — | EP | claimed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| CN-109589324-A | The therapeutic agent of angle disorder of conjunctiva | 国立大学法人山口大学 | 2019-04-09 | — | — | CN | claimed |
| CN-105188753-B | Therapeutic agent for keratoconjunctival disorder | 国立大学法人山口大学 | 2018-12-18 | — | — | CN | claimed |
| EP-2224908-B1 | COMPOSITIONS CONTAINING AT LEAST ONE NAPHTHOIC ACID DERIVATIVE, BENZOYL PEROXIDE AND AT LEAST ONE FILM-FORMING AGENT, METHODS FOR PREPARING SAME AND USES THEREOF | GALDERMA RES & DEV (FR) | 2017-11-01 | — | — | EP | claimed |
| EP-0850067-A4 | METHOD FOR TREATING CANCERS USING 6- 3- 1-ADAMANTYL]-4-HYDROXYPHENYL] | CIRD GALDERMA (FR) | 1999-12-15 | — | — | EP | claimed |
| US-6001885-A | INHIBITING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) EXPRESSION IN KERATINOCYTES BY ADMINISTERING AT LEAST ONE RETINOID; USEFUL FOR TREATING DISEASES RELATING TO VEGF OVEREXPRESSION, SUCH AS PSORIASIS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) | 1999-12-14 | — | — | US | claimed |
| EP-0920312-A1 | APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS | Galderma Research & Development (FR) | 1999-06-09 | — | — | EP | claimed |
| CN-1203528-A | RAR-gamma specific agonist ligands for increasing apoptosis rate | GENTRE INTERNATIONAL DE RECH D (FR) | 1998-12-30 | — | — | CN | claimed |
| EP-0862910-A2 | Use of retinoids as skin pigmentation inducing agent | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1998-09-09 | — | — | EP | claimed |
| WO-1998037053-A1 | IDENTIFICATION OF A UNIQUE RECEPTOR SPECIFIC FOR A PARTICULAR RETINOID INDUCING CELLULAR APOPTOSIS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 1998-08-27 | — | — | WO | claimed |
| EP-0850067-A1 | METHOD FOR TREATING CANCERS USING 6- 3- 1-ADAMANTYL]-4-HYDROXYPHENYL] | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1998-07-01 | — | — | EP | claimed |
| WO-1998001132-A1 | APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-01-15 | — | — | WO | claimed |
| WO-1997003682-A1 | METHOD FOR TREATING CANCERS USING 6-[3-[1-ADAMANTYL]-4-HYDROXYPHENYL] | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. GALDERMA (FR) | 1997-02-06 | — | — | WO | claimed |
| EP-0199636-B1 | BENZONAPHTHALENIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN PHARMACY AND COSMETICS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. Groupement d'Intérêt Economique dit: (FR) | 1989-02-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016148-A1 | RETINOIC ACID RECEPTOR GAMMA AGONISTS TO ATTENUATE ANTHRACYCLINE-INDUCED CARDIOTOXICITY | RARG, RXRG, RARA | RARG 1/4885RARB 4/4885RARA 3/4885 |
| US-11135236-B2 | Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity | RARG, RXRG, RARA | RARG 1/4885RARB 4/4885RARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.